Cited by 686Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

André, Thierry, de Gramont, Armand, Vernerey, Dewi, Chibaudel, Benoist, Bonnetain, Franck, Tijeras-Raballand, Annemilaï, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean Luc, Banzi, Maria, Maartense, Eduard, Shmueli, Einat, Carlsson, Goran U., Scheithauer, Werner, Papamichael, Demetris, Möehler, Marcus, Landolfi, Stefania, Demetter, Pieter, Colote, Soudhir, Tournigand, Christophe, Louvet, Christophe, Duval, Alex, Fléjou, Jean-François, de Gramont, Aimery·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2015.63.4238

Open this paper in CoChat — free account

Abstract

Purpose: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods: Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results: After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. Conclusion: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.4238

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,436
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P. N., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,055

Show all 32 references

Sorted by citations

Items 401–500 of 686

The diagnostic accuracy of local staging in colon cancer based on computed tomography (CT): evaluating the role of extramural venous invasion and tumour deposits
van den Berg, K., Wang, S., Willems, J., Creemers, G. J., Roodhart, J. M. L., Shkurti, J., Burger, J. W. A., Rutten, H. J. T., Beets‐Tan, R. G. H., & Nederend, J. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04094-7 · Cited by 6
Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence
Piercey, O., Wong, H., Leung, C., To, Y. H., Heong, V. Y. M., Lee, M., Tie, J., Steel, M., Yeung, J. M. C., McCormick, J. J., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.01.001 · Cited by 6
Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers
Jafry, B. H., Buhaya, M. H., Milsap, A., Jones, A. L., Goksu, S. Y., Verma, N., Brown, T. J., Hughes, A. E., Nair, R. G., Sanford, N. N., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.04.003 · Cited by 7
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
Fazio, R., Audisio, A., Daprà, V., Conti, C., Benhima, N., Abbassi, F.-Z., Assaf, I., Hendlisz, A., & Sclafani, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102752 · Cited by 6
What is the optimal duration of adjuvant therapy in colon cancer?
Shields, A. F. (2017) · PubMed · Cited by 6
Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability
Matos, P., & Jordan, P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_2 · Cited by 6
Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial
Bauman, B., Mick, R., Martinez, E., Lawless, T., Zinck, L. J., Sinclair, P., Fuhrer, M. J., O’Hara, M. H., Schneider, C. J., O'Dwyer, P. J., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7110 · Cited by 6
Molecular Lymph Node Staging with One‐Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow‐up Study
Weixler, B., da Cunha, S. T., Warschkow, R., Demartines, N., Güller, U., Zettl, A., Vahrmeijer, A. L., van de Velde, C. J. �., Viehl, C. T., & Zuber, M. (2021) · World Journal of Surgery · doi:10.1007/s00268-020-05949-6 · Cited by 6
Die neoadjuvante und adjuvante Therapie des resektablen Kolonkarzinoms: Aktuelle Standards und Entwicklungen
Heinemann, V., & Stintzing, S. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1391-5124 · Cited by 6
Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma
Jang, S. I., Cho, J. H., Kim, S.-Y., Hong, I.-Y., Park, J. S., Lee, H. S., Park, G., Kim, J. K., Lee, H. K., & Lee, D. K. (2022) · Cancers · doi:10.3390/cancers14030853 · Cited by 6
The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective
Bregni, G., Rebuzzi, S. E., & Sobrero, A. F. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0600-2 · Cited by 6
Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study
Li, K., Zhao, F., Guo, Y., Wu, Q., Luo, S., Zhang, J., Li, H., Hu, S., Wu, B., Lin, G., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11196-4 · Cited by 5
Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12)
Cha, Y., Cho, S., Park, E. Y., Lee, D., Park, T., Choi, M. K., Hwang, I. G., Beom, S., Kang, B. W., Kim, J.-S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14746-0 · Cited by 5
The role of hypoxia-inducible factor-1α on colon cancer progression and metastasis
Saadh, M. J., Ahmed, M. H., Albadr, R. J., Sanghvi, G. V., Roopashree, R., Kashyap, A., Sabarivani, A., Rizaev, J. A., Taher, W. M., Alwan, M., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02906-y · Cited by 5
Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors
Kwak, Y., Bae, J. M., & Lee, H. S. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.1161 · Cited by 5
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)—an AIO/ABCSG trial
Folprecht, G., Stasik, S., Reinacher-Schick, A. C., Weiss, L., Goekkurt, E., Jacobasch, L., Conradi, L., Kröcher, A., Hofheinz, R. D., Liersch, R., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.05.001 · Cited by 6
Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study
Liu, L., & Xiang, Z. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221137758 · Cited by 5
TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma
Chi, X.-J., Song, Y.-B., Liu, D.-H., Wei, L.-Q., Zhao, A., An, X., Feng, Z.-Z., Lan, X.-H., Lv, Y.-M., Li, H.-J., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02927-9 · Cited by 5
Mortality Outcome Associated with Specific KRAS, NRAS, and BRAF Hot-Spot Mutations in Metastatic Colorectal Cancer Patients: A Retrospective Cohort Study
Abdelgadir, O., Kuo, Y., Khan, M. F., Okorodudu, A. O., Cheng, Y., & Dong, J. (2025) · Diagnostics · doi:10.3390/diagnostics15050590 · Cited by 5
Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study
Keikes, L., Koopman, M., Lemmens, V. E. P. P., van Oijen, M. G. H., & Punt, C. J. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14436 · Cited by 5
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
Hanna, C. R., Robles‐Zurita, J. A., Briggs, A. H., Harkin, A., Kelly, C., McQueen, J., Allan, K., Pearson, S. R., Holländer, N. H., Glimelius, B. L. G., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.04.001 · Cited by 5
Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment
Koulouridi, A., Messaritakis, I., Theodorakis, E., Chondrozoumaki, M., Sfakianaki, M., Gouvas, N., Tsiaoussis, J., Mavroudis, D., Tzardi, M. N., & Souglakos, J. (2021) · Cancers · doi:10.3390/cancers13143552 · Cited by 5
Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2021) · Der Chirurg · doi:10.1007/s00104-021-01486-7 · Cited by 5
Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer
Morris, V. K., Kee, B. K., Overman, M. J., Dasari, A. N., Raghav, K. P. S., Johnson, B., Parseghian, C. M., Wolff, R. A., Garg, N., Eng, C., et al. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-471 · Cited by 5
The lncRNA TRG-AS1 promotes the growth of colorectal cancer cells through the regulation of P2RY10/GNA13
Shi, L., Luo, B., Deng, L., Zhang, Q., Li, Y., Sun, D., Zhang, H., & Zhuang, L. (2024) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2024.2318363 · Cited by 5
Dissecting microsatellite instability in colorectal cancer: one size does not fit all
Samstein, R. M., & Chan, T. A.-T. (2017) · Genome Medicine · doi:10.1186/s13073-017-0438-9 · Cited by 5
Lower serum CA125 level, negative vascular invasion, and wild BRAF were strongly associated with better 2-year disease-free survival in patients with stage III colorectal cancer who received adjuvant chemotherapy
Chang, S.-J., Ge, X., Xu, Z., Qi, X., & Chen, X.-P. (2018) · Cancer Biomarkers · doi:10.3233/cbm-181179 · Cited by 5
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
Kotaka, M., Iwamoto, S., Satake, H., Sakai, D., Kudo, T., Fukunaga, M., Konishi, K., Ide, Y., Ikumoto, T., Tsuji, A., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01701-1 · Cited by 5
Three Versus Six Months of Adjuvant Oxaliplatin-Containing Chemotherapy for Patients With Stage III Colorectal Cancer: A Contemporary Real-World Analysis
Krishnan, T., Leung, E. W., Vasconcelos, J. P. S., Lim, H. J., Loree, J. M., Davies, J. M., Gill, K., & Gill, S. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00492 · Cited by 4
High-fat diet driven post-operative colon cancer recurrence is dependent upon genetic susceptibility to deoxycholic acid
Morgan, R. B., Tork, M. A. B., Lin, Z., Wild, C. E., Frietze, L. R., Huang, S., Roh, M., Olivas, A. D., Steele, C. W., Pan, T., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217943 · Cited by 4
A comparison by mismatch repair status of real‐world characteristics and outcomes in patients with stage II / III rectal cancer in the Netherlands
Lunenberg, R. A., Franken, I. A., van der Baan, F. H., Sijtsma, F. P. C., Vink, G. R., Braat, M. N. G. J. A., Moons, L. M. G., Laclé, M. M., Elferink, M. A. G., Boklage, S., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70127 · Cited by 5
An Immune-Related Prognostic Risk Model in Colon Cancer by Bioinformatics Analysis
Lai, Q., & Feng, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3640589 · Cited by 4
Retracted
Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer
Adams, A. M., Vreeland, T. J., & Newhook, T. E. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00888-y · Cited by 4
Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients
Zhu, W., Wu, C., Hu, S., Liu, S., Zhao, S., Zhang, D., Qiu, G., Cheng, X., & Huang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-48623-2 · Cited by 4
Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis
Oh, S. Y., Kim, C. W., Kim, S., Kim, M. H., Kim, Y. I., Lee, J. L., Yoon, Y. S., Park, I. J., Lim, S., & Yu, C. S. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.04.002 · Cited by 4
High expression of PAX8-AS1 correlates with poor prognosis and response to fluorouracil-based chemotherapy in stage II colon cancer
Fang, H., Han, L., Xu, Y., Gu, R., Cai, G., Xia, Z., Dai, W., & Wang, R. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102128 · Cited by 4
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival
Ando, K., Emi, Y., Miyanari, N., Tsuji, A., Sakai, K., Sawai, T., Imamura, H., Mori, S., Tokunaga, S., Oki, E., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01646-5 · Cited by 4
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin‐Based Chemotherapy? A Multidisciplinary Inter‐Group Survey
Nassar, A., Phelip, J., Goèré, D., Loriau, J., Gallois, C., Michel, P., Penna, C., Taı̈eb, J., Brouquet, A., & Benoist, S. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05837-z · Cited by 4
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Saad, E. D., & Buyse, M. E. (2020) · Cancers · doi:10.3390/cancers12113442 · Cited by 5
In vitro and in vivoactivity of series of cationic dinuclearPt(II) complexes
Vasić, I., Rajković, S., Arsenijević, A., Milovanović, M., Arsenijević, N., Milovanović, J., & Živković, M. D. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111619 · Cited by 4
Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey
Kasi, A., Dotan, E., Poage, G. M., Catteau, A., Vernerey, D., George, M., & Barzi, A. (2021) · Cancers · doi:10.3390/cancers13215467 · Cited by 4
Self-citation
Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer
Shahi, F., Gorji, M., Payandeh, M., Rezvani, H., Vaezi, M., Seifi, S., Baari, A., Dizaji, R. K., Hashemi, S. M., Salimi, S., et al. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100657 · Cited by 4
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
Boku, S., Satake, H., Ohta, T., Mitani, S., Kawakami, K., Suzuki, Y., Matsumoto, T., Terazawa, T., Yamazaki, E., Hasegawa, H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0949 · Cited by 4
Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer
Qu, A., Wang, Q., Chang, Q., Liu, J., Yang, Y., Zhang, X., Zhang, Y. L., Zhang, X., Wang, H., & Zhang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-022-25852-5 · Cited by 4
The Future of Interventions for Stage IV Colorectal Cancers
Lloy, S., Lin, M., Franko, J., & Raman, S. R. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1761624 · Cited by 4
Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
Tan, S. X., Pumpalova, Y. S., Rogers, A. M., Bhatt, K. A., Herbst, C., Ruff, P., Neugut, A. I., & Hur, C. (2023) · Cancer Medicine · doi:10.1002/cam4.6199 · Cited by 3
The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer
Chan, W. Y., Chua, W. M., Wilkinson, K. J., Epitakaduwa, C., Mandaliya, H. A., Descallar, J., Roberts, T. L., Becker, T. M., Ng, W. L., Lee, C. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168673 · Cited by 4
CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer
Hashizume, R., Kawahara, H., Ogawa, M., Suwa, K., Eto, K., & Yanaga, K. K. (2019) · In Vivo · doi:10.21873/invivo.11708 · Cited by 4
The Clinical Significance of Microsatellite Instability in Precision Treatment
Huang, Z., Chen, X., Liu, C., & Cui, L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_3 · Cited by 4
ASCO- und ESMO-Update 2017 – Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017
Ettrich, T. J., Ebert, M. P., Lorenzen, S., Moehler, M. H., Vogel, A., Witkowski, L., Seufferlein, T. T. W., & Reinacher‐Schick, A. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0044-101757 · Cited by 4
A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancer
Treasure, M. E., Thomas, A., Ganocy, S. J., Hong, A., Krishnamurthi, S., Bajor, D. L., Berger, N. A., & Meropol, N. J. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-330 · Cited by 4
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping
Magnes, T., Melchardt, T., Weiß, L., Hufnagl, C., Greil, R., & Egle, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6057 · Cited by 4
How Strong Is the Evidence Supporting Thromboprophylaxis in Surgical Oncology?
Klemen, N. D., Feingold, P. L., & Hashimoto, B. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01934 · Cited by 4
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
Bardakçı, M., Esmer, D. D., Hafızoğlu, E., Yaslıkaya, Ş., Genç, T. B., Özçelik, M., Erdat, E. C., Hendem, E., Büyükbayram, M. E., Topcu, Z. A., et al. (2023) · Oncology · doi:10.1159/000531722 · Cited by 3
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency
Fukuda, K., Kasuga, A., Shigematsu, Y., Kato, K., Ito, H., Ueki, A., Okamoto, T., Ozaka, M., Takahashi, Y., & Sasahira, N. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02122-1 · Cited by 3
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care
Jeon, J. Y. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01071-5 · Cited by 3
Risk of second primary malignancies after adjuvant chemotherapy for colon cancer
Büchler, T., Ambrožová, M., Májek, O., Dianova, T., Klika, P., & Dušek, L. (2025) · Cancer · doi:10.1002/cncr.70116 · Cited by 3
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., et al. (2025) · Current Oncology · doi:10.3390/curroncol32110624 · Cited by 3
The prognostic impact of lymph node yield in deficient and proficient mismatch repair colon cancers: A retrospective national cohort study
Bækgaard, F. W., Iordache, A., Nordholm, A. H., Krarup, P., Schlesinger, N. H., Qvortrup, C., & Smith, H. G. (2025) · Colorectal Disease · doi:10.1111/codi.70332 · Cited by 3
Implementing Immunoscore in colorectal cancer: lessons from cohort studies, limitations and barriers to adoption
Hsu, M. S. S., & Leung, S. Y. (2025) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70071 · Cited by 3
In Vitro Antitumor Effects of Melittin Attached to Fe3O4 Magnetic Nanoparticles with Synergistic Contribution of Magnetic Hyperthermia
Câmpian, A., Bâldea, I., Muntean, M., Iacoviță, C., & Florea, A. (2026) · Molecules · doi:10.3390/molecules31122171 · Cited by 3
Sporadic and Inherited Colorectal Cancer: How Epidemiology and Molecular Biology Guide Screening and Treatment
Glasgow, S. C., & Hardiman, K. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-66049-9_22 · Cited by 3
Tumors of the Small Intestine, Colon, and Rectum
Signoroni, S., Bartolomeo, M. D., & Ferrari, A. (2022) · Pediatric oncology · doi:10.1007/978-3-030-92071-5_25 · Cited by 3
Current Status of Chemotherapy in Colorectal Cancer: Updated Treatment Strategies
Kim, J. H., & Park, S. J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.087 · Cited by 3
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
Cohen, R., Raeisi, M., Chibaudel, B., Yothers, G., Goldberg, R. M., Bachet, J., Wolmark, N., Yoshino, T., Schmoll, H., Haller, D. G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104481 · Cited by 4
Self-citation
Jagged-1 Expression Level Is Correlated With Recurrence of Stage III Colorectal Cancer in Patients Receiving Adjuvant Chemotherapy
Kim, H.-B., LEE, S.-B., Kim, S., Lee, H.-J., & Park, S.-G. (2021) · Anticancer Research · doi:10.21873/anticanres.15278 · Cited by 3
SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study
You, D., Zhang, S., Yan, S., Ding, Y., Li, C., Cheng, X., Wu, L., Wang, W., Zhang, T., Li, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939982 · Cited by 3
The prognostic value of circulating in blood tumor DNA as a marker of minimal residual disease in stage I–III colorectal cancer
Максимовна, П. Е., Fedyanin, M. Y., Boyarskikh, U. A., Андреевич, К. А., Анатольевна, М. Е., Khrapov, E. A., Oskorobin, I. P., Shamovskaya, D. V., Алиев, В. А., Mammadli, Z., et al. (2022) · Advances in molecular oncology · doi:10.17650/2313-805x-2022-9-2-32-42 · Cited by 3
Prognostic value of elastic lamina staining in patients with stage III colon cancer
Bi, F., Li, X., Zhang, Y., Wang, Z., Dong, Q., Zhang, J., & Sun, D. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02865-y · Cited by 3
Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol
Justesen, T. F., Gögenür, I., Tarpgaard, L. S., Pfeiffer, P., & Qvortrup, C. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073372 · Cited by 3
Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan
Yu, Y.-L., Tseng, W., Liao, C., Yeh, C.-Y., Chen, H., Liu, Y.-H., Liaw, Y.-W., & Fan, C. (2023) · BMC Cancer · doi:10.1186/s12885-023-11310-6 · Cited by 3
Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study
To, Y. H., Gibbs, P., Tie, J., Loree, J. M., Glyn, T., & Degeling, K. (2023) · Cancers · doi:10.3390/cancers15215227 · Cited by 3
Predictors of Timely Initiation and Completion of Adjuvant Chemotherapy in Stage II/III Colorectal Adenocarcinoma
Alnajjar, S., Shoucair, S., Almanzar, A., Zheng, K., Lisle, D. M., & Gupta, V. K. (2024) · The American Surgeon · doi:10.1177/00031348241248689 · Cited by 3
Mismatch Repair Status and Surgical Outcomes in Localized Colorectal Cancer: A Nationwide Cohort Study
Justesen, T. F., Orhan, A., Rosen, A. W., Gögenur, M., & Gögenür, I. (2024) · Annals of Surgery Open · doi:10.1097/as9.0000000000000499 · Cited by 4
INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases
Patel, S., Seshadri, R. A., Saklani, A. P., Somashekhar, S. P., Rohit Kumar, C., Singh, S., Sukumar, V., & Bhatt, A. (2024) · JCO Global Oncology · doi:10.1200/go-24-00306 · Cited by 3
Emerging therapeutic strategies in Lynch syndrome-associated colorectal cancer and the role of MMR testing
Negro, S., Perissinotto, E., Mammi, I., Crivellari, G., Schiavi, F., Cappello, F., Spolverato, G., Ferrari, D., Rausa, E., Vitellaro, M., et al. (2025) · Tumori Journal · doi:10.1177/03008916241310706 · Cited by 3
Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer
Xu, J., Li, X., & Lv, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7119 · Cited by 3
Therapeutische Relevanz molekularer Marker beim kolorektalen Karzinom
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2020) · Der Onkologe · doi:10.1007/s00761-020-00777-8 · Cited by 3
Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo, M., Piercey, O., & Tie, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01137-4 · Cited by 3
The impact of time to surgery on oncological outcomes in stage I-III dMMR colon cancer – A nationwide cohort study
Justesen, T. F., Gögenur, M., Clausen, J. S. R., Mashkoor, M., Rosen, A. W., & Gögenür, I. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.03.223 · Cited by 3
Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer
Miyamoto, Y., Zhang, W., & Lenz, H. (2016) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-016-0543-z · Cited by 3
SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.
Han, X., Wang, Z., Zhang, L., Shen, Y., Tan, Q., Sun, Y., Wang, J., Qian, X., Yang, H., & Shi, Y. (2021) · PubMed Central · Cited by 3
Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53
Wang, W.-L., Batzorig, U., Hung, C., Wei, P., Huang, C., & Chang, Y. (2022) · BioMed Research International · doi:10.1155/2022/1322788 · Cited by 3
New Insights into Adjuvant Therapy for Localized Colon Cancer
Gonzalez, N. S., Ros, J., Illescas, D. G., Argota, I. B., Ballabrera, F. S., & Elez, M. E. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.006 · Cited by 5
Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
Zhang, C., Zhan, Y., Ni, K., Liu, Z., Xin, R., Han, Q., Li, G., Ping, H., Liu, Y., Zhao, X., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10266-3 · Cited by 4
Immunotherapy for Colorectal Cancer
Zhang, C., COX, R. A., & Chakrabarti, S. (2025) · Springer eBooks · doi:10.1007/978-3-030-80962-1_220-1 · Cited by 3
Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases
Takenami, T., Tsujinaka, S., Takahashi, J. A., Tamaki, S., Maemoto, R., Fukuda, R., Ishikawa, H., Kakizawa, N., Hasegawa, F., Kikugawa, R., et al. (2019) · Case Reports in Surgery · doi:10.1155/2019/8129358 · Cited by 3
Putting IDEA's Results Into Practice: Practicality Should Rule Complexity in Stage III Colon Cancer
Sanoff, H. K. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00466 · Cited by 3
The clinical dilemma of high-risk stage II colon cancer: are we truly prepared to withdraw oxaliplatin?
Taı̈eb, J., Gandini, A., Seligmann, J. F., & Gallois, C. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.104072 · Cited by 3
Patients with T4N0 and T1‑3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months
Inoue, H., Shimizu, H., Kuriu, Y., Arita, T., Nanishi, K., Kiuchi, J., Ohashi, T., Yamamoto, Y., Konishi, H., Morimura, R., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14759 · Cited by 2
Characteristics, Treatment and Outcomes of Stage I to III Colorectal Cancer in Patients Aged over 80 Years Old
Yeo, M. R., & Voutsadakis, I. A. (2025) · Cancers · doi:10.3390/cancers17020247 · Cited by 2
Association Between Deficient MSH2/MSH6 Versus MLH1/PMS2 Status and Survival Rates in Localized Colorectal Cancer
Justesen, T. F., Orhan, A., Rosen, A. W., Gögenur, M., Krarup, P., Qvortrup, C., & Gögenür, I. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006628 · Cited by 2
Critical Evaluation of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Ubink, M., Verheul, H. M. W., Verhoef, C. K., & Tanis, P. J. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00530 · Cited by 2
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
Kuznetsova, O. A., Zagidullina, A. A., Drobot, N. T., Prokopiev, A., Ivanov, M. V., Fedyanin, M. Y., Mamedli, Z. Z., Алиев, В. А., Polynovskiy, A. V., Dzhumabaev, K., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00602 · Cited by 2
Research progress on early diagnostic biomarkers and liquid biopsy technologies for colorectal cancer: a comprehensive review
Shen, H., Wang, Z., & Zhang, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1720447 · Cited by 2
The Value of Sentinel Lymph Node Mapping for the Staging of Node-Negative Colon Cancer
Weixler, B., Ramser, M., Warschkow, R., Viehl, C. T., Vaughan-Shaw, P. G., Zettl, A., Kettelhack, C., & Zuber, M. (2021) · Annals of Surgery Open · doi:10.1097/as9.0000000000000084 · Cited by 2
What is precision medicine in oncology?
Arbitrio, M., Cordua, A., Uppolo, V., D’Apolito, M., Caracciolo, D., Staropoli, N., Cuomo, O., Fiorillo, L., Tassone, P., Martino, M. T. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822703-9.00002-8 · Cited by 2
Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved
Ioffe, D., McSweeny, M. J., & Hall, M. J. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770385 · Cited by 2
The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II–III Colorectal Cancer: A Retrospective Multi-Center Cohort Study
Liu, L., Pang, X., Zhao, K., Chen, Y., Li, Y., You, R., Xu, T., Liu, M., Wu, L., Li, Z., et al. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s420024 · Cited by 2
Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
Rosberg, V., Jessen, M., Qvortrup, C., Smith, H. G., & Krarup, P. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2251086 · Cited by 4

Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
André, T., de Gramont, A., Chibaudel, B., Tijeras‐Raballand, A., Duval, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.5 · Cited by 3
Self-citation
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Fléjou, J., André, T., Chibaudel, B., Scriva, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., Shani, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3524 · Cited by 23
Self-citation
Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
Taı̈eb, J., Zaanan, A., Malicot, K. L., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J. M., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 164
Self-citation
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 285

See all

Authors: André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., Banzi, M., Maartense, E., Shmueli, E., Carlsson, G. U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J.-F., & de Gramont, A.
Affiliations: Inserm (FR)
Thierry André and Jean-François Fléjou, Hôpital St Antoine; Thierry André and Jean-François Fléjou, University Pierre et Marie Curie Paris VI; Thierry André, Benoist Chibaudel, Annemilaï Tijeras-Raballand, Soudhir Colote, and Aimery de Gramont, Groupe Coopérateur Multdisciplinaire en Ocologie (GERCOR) Oncology Multidisciplinary Group and GERCOR-Innovative Research Consortium; Christophe Louvet, Institut Mutualiste Montsouris; Alex Duval, L'Institut National de la Santé et de la Recherche Médicale UMRS...
ORCID: André, Thierry
Chibaudel, Benoist
Hickish, Tamas
Tabernero, Josep
Banzi, Maria
Shmueli, Einat
Papamichael, Demetris
Landolfi, Stefania
Demetter, Pieter
Tournigand, Christophe
Louvet, Christophe
Duval, Alex
Fléjou, Jean-François
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-12-10
Volume: 33
Issue: 35
Pages: 4176-4187
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2015.63.4238
OpenAlex: W1960485012
Cited by: 683
References: 32
Citations by year: 2026: 43 · 2025: 56 · 2024: 75 · 2023: 65 · 2022: 74 · 2021: 92 · 2020: 97 · 2019: 47 · 2018: 59 · 2017: 41 · 2016: 32
FWCI: 19.22
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: European Society for Medical Oncology
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: colon cancer, adjuvant chemotherapy, oxaliplatin, FOLFOX4, 5-fluorouracil, leucovorin, BRAF mutation, mismatch repair deficiency, overall survival, disease-free survival, prognostic factors, stage II colon cancer, stage III colon cancer, mosaic studies, long-term follow-up, microsatellite instability, mismatch repair proteins
MeSH terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Colonic Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Intravenous, Male, Middle Aged, Mutation, Neoplasm Staging, Organoplatinum Compounds, Prognosis, Valine, Odds Ratio, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Glutamic Acid, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks